- Home
- PRAX vs ADTN Comparison
PRAX vs ADTN Comparison
Compare PRAX & ADTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRAX
- ADTN
- Stock Information
- Founded
- PRAX 2015
- ADTN 1985
- Country
- PRAX United States
- ADTN United States
- Employees
- PRAX N/A
- ADTN N/A
- Industry
- PRAX Biotechnology: Pharmaceutical Preparations
- ADTN Telecommunications Equipment
- Sector
- PRAX Health Care
- ADTN Telecommunications
- Exchange
- PRAX Nasdaq
- ADTN Nasdaq
- Market Cap
- PRAX 599.7M
- ADTN 616.5M
- IPO Year
- PRAX 2020
- ADTN 1994
- Fundamental
- Price
- PRAX $38.55
- ADTN $8.03
- Analyst Decision
- PRAX Strong Buy
- ADTN Strong Buy
- Analyst Count
- PRAX 10
- ADTN 4
- Target Price
- PRAX $116.50
- ADTN $12.00
- AVG Volume (30 Days)
- PRAX 320.6K
- ADTN 888.9K
- Earning Date
- PRAX 05-02-2025
- ADTN 05-07-2025
- Dividend Yield
- PRAX N/A
- ADTN N/A
- EPS Growth
- PRAX N/A
- ADTN N/A
- EPS
- PRAX N/A
- ADTN N/A
- Revenue
- PRAX $8,122,000.00
- ADTN $944,291,000.00
- Revenue This Year
- PRAX N/A
- ADTN $13.90
- Revenue Next Year
- PRAX N/A
- ADTN $9.13
- P/E Ratio
- PRAX N/A
- ADTN N/A
- Revenue Growth
- PRAX 270.02
- ADTN N/A
- 52 Week Low
- PRAX $26.70
- ADTN $4.62
- 52 Week High
- PRAX $91.83
- ADTN $12.44
- Technical
- Relative Strength Index (RSI)
- PRAX 53.72
- ADTN 49.80
- Support Level
- PRAX $35.21
- ADTN $7.65
- Resistance Level
- PRAX $38.90
- ADTN $8.24
- Average True Range (ATR)
- PRAX 2.09
- ADTN 0.27
- MACD
- PRAX 0.07
- ADTN 0.02
- Stochastic Oscillator
- PRAX 69.58
- ADTN 37.62
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.
About ADTN ADTRAN Holdings Inc.
Adtran Holdings Inc is a provider of networking and communications platforms, software, and services focused on the broadband access market. It operates under two reportable segments: Network Solutions, which includes hardware and software products that enable a digital future that supports the company's Subscriber, Access & Aggregation, and Optical Networking Solutions; and Services & Support Segment which includes network design, implementation, maintenance and cloud-hosted services supporting the company's Subscriber, Access & Aggregation, and Optical Networking Solutions.